Forth raise £1.6m to launch ground-breaking femtech product

Posted by 

SETsquared Bristol

SETsquared Bristol member, Forth, is set to capitalise on the growth in the female science and technology market as it has secured £1.6m funding to support the launch of its ground-breaking female health product.

Leading the team at Forth is CEO and Co-founder Sarah Bolt. She said: “Today, more and more people are realising that understanding and measuring your body’s biochemistry is key for a long and healthy life. For women in particular, gaining unique insight into how their hormone levels fluctuate throughout their unique cycle can give women the support they have been lacking and help to close the gender health gap”.

Forth’s investment round has attracted backing from a consortium of both UK and overseas investors including, Trajan Scientific and Medical, (Trajan) through its European subsidiary Trajan Scientific Europe Ltd . Headquartered in Melbourne, Australia, Trajan is a global developer and manufacturer of analytical science instruments, devices and solutions and has major operations in Australia, Europe, US and Asia.

Stephen Tomisich, Chief Executive Officer and Managing Director, Trajan stated, “We have known the founders and majority shareholders at Forth for some time. We share common values around delivering good science that helps people achieve better health outcomes. We are both intensely focused on delivering impact and working together we believe we will do just that.”

The Development Bank of Wales has also supported this second round of funding with follow-on equity of £250,000 bringing its total investment to date to £500,000. Senior Investment Executive Alexander Leigh said: “Sarah and the team have done incredibly well to secure a strong market position in a rapidly growing sector. The company is ranked by Trustpilot as the highest rated service in the sector and has all the drive and the skills to deliver on their vision.

“Our follow-on equity funding coupled with Trajan’s strategic investment will now give Forth unique access to cutting edge technologies as they develop their innovative product offering with Female Hormone Mapping. We‘re proud to be behind this great team and wish them every success.”

Forth reported revenue growth of over 100% in June 2020 compared to the previous year. The company was then awarded an innovation grant in September 2020 to develop a unique female hormone product.  In 2020 founder and CEO, Sarah Bolt won Health & Wellbeing Entrepreneur of the Year for Wales at the Great British Entrepreneur Awards and is currently a finalist for the Natwest Everywoman Award.

Sarah Bolt added: “Our mission at Forth is simple – to give people a better understanding of their own body using a combination of science and technology. This investment will enable us to launch Female Hormone Mapping and also develop more unique and insightful products to help people engage proactively with their health. Trajan is a perfect partner as we share a focus on using science to advance preventative health while the Development Bank continues to support us as a Welsh-based company that is at the forefront of the femtech market.”

 

For more information on SETsquared Bristol news, opportunities and events, sign up to receive the monthly newsletter.

Find out about our current projects at SETsquared

Recent News, Blogs and Stories

DRIFT Energy’s fleet of net positive ships (MVY – Most Valuable Yachts) - credit DRIFT Energy

DRIFT Energy plans first green hydrogen-producing vessel build following seed investment

DRIFT Energy has announced the close of its seed funding round led by Octopus Ventures, and with support from Blue Action Accelerator, the company has secured a total of £4.65...
FluoretiQ founders smiling with technology on PC

FluoretiQ patent granted to enable fast and accurate antibiotic testing

Bristol-based biotech company, FluoretiQ, who is developing fast and accurate point-of-care testing for Urinary Tract Infections (UTIs) and Sexually Transmitted Diseases (STDs), has taken a significant step forward after having...
GenomeKey blood sample in lab

GenomeKey awarded $11.4M to transform sepsis diagnosis and treatment

GenomeKey has been awarded a major grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to build a functioning, automated prototype of their desktop diagnostic device. The Bristol-based company joined our...

SUCCESS IS THE GOAL

Fast track your technology business